UNSPSC 51422204: Triamcinolone

This classification denotes a therapeutic glucocorticoid with the molecular formula C21H27FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1ZK20VI6TY, chemically known as pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11.beta.,16.alpha.)- but generally known as triamcinolone, which bears US NIH Compound Identifier 5544. European Medicines Agency schedules Triamcinolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11251MIG.

UNSPSC 51422204 Triamcinolone is a Commodity code that reflects state and local procurement of pharmaceutical products, though recent solicitation activity tagged under this code does not align with triamcinolone specifically. The source shows activity in emergency-response pharmaceuticals and pharmacy benefit management infrastructure rather than this steroid compound. Issuing bodies include county health departments and state health and human services commissions, which solicit pharmaceutical procurement through competitive bidding and exploratory market-intelligence mechanisms to support community health programs and managed pharmacy initiatives.

Recent opportunities span Florida and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building, response due July 26, 2023, on a two-year term with one-year renewal option; the Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs that would bypass traditional pharmacy benefit managers and wholesalers, with a response deadline of April 3, 2026. The Seminole County procurement requires E-Verify compliance, drug-free workplace certification, and standard commercial insurance; the Texas RFI targets vendors with prior direct-contracting experience in self-insured group health plans and government sectors and capability to negotiate net-pricing models without rebates. Neither opportunity specifies set-aside designations. The mismatch between the code's nominal scope (triamcinolone) and the actual recent solicitations (naloxone, pharmacy logistics infrastructure) signals that this code sees limited relevant state and local activity aligned with its pharmaceutical classification.